Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.
Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.
Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).
Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.
Merck Serono, a division of Merck KGaA, Darmstadt, Germany announces today that it will be presenting new data from several studies of Erbitux (cetuximab) in a range of solid tumor types including the first Phase II data in breast and prostate cancers. These data will be presented at the forthcoming 35th European Society for Medical Oncology Congress (ESMO) in Milan, October 8-12, 2010.
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that researchers have identified two unique gene clusters that differentiated subjects who responded to treatment in the Company’s phase 2a proof of concept study of SCV-07 for the prevention of severe oral mucositis (OM; WHO grades 3-4) in patients with advanced head and neck cancer.
IsoRay Inc. a medical isotope company and the exclusive manufacturer of Cesium-131 used in internal radiation therapy for the treatment of lung, colon, head and neck, and prostate cancers, ocular melanoma, and other malignant disease through the use of its proprietary radioisotope technology, announced its financial results for the year ended June 30, 2010.
Head and neck cancer outcomes associated with race may be more closely linked to social and behavioral factors than biological differences, especially for African Americans, according to a new Henry Ford Hospital study.
Molecularly targeted therapies can reduce tumors rapidly. However, not all tumors respond to the drugs, and even those that do often develop resistance over time. Looking for a way to combat the problem of resistance, researchers at Fox Chase Cancer Center hypothesized that hitting already weakened cancer cells with a second targeted agent could kill them-but only if it was the right second agent.
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care signed a $30 million supply agreement for MuGard with RHEI Pharmaceuticals, Inc., a specialty pharmaceutical company focused on bringing proprietary medicines to the China market. Access will ensure manufacturing capacity of up to a minimum of $30 million of product in the licensed territories.
Accuray Incorporated, a global leader in the field of radiosurgery, announced today that for the first time in Europe the company showcased its latest offering, the CyberKnife VSI System, at ESTRO 29, the Annual Congress of the European Society for Therapeutic Radiology and Oncology in Barcelona, Spain.
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has launched www.MuGard.com. The patient- and healthcare professional- focused site is a comprehensive resource offering educational material on oral mucositis, patient analysis, MuGard product and how-to-order information.
The recent news that Michael Douglas has been diagnosed with stage 4 throat cancer has raised public awareness of head and neck cancer. What causes throat cancer and what are the symptoms? Are there ways to prevent or reduce the risk of throat cancer? How is the human papillomavirus (HPV) related to oral cancer?
CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.
An incisionless robotic surgical procedure is offering patients a new option to remove certain head and neck cancer tumors without visible scarring, while preserving speech and the ability to eat.
Only one in ten people know that radiotherapy helps cure forty per cent of cancer patients according to new figures published by Cancer Research UK today.
Recent studies have shown that acupuncture can help control a number of symptoms and side effects such as pain, fatigue, dry mouth, nausea, and vomiting associated with a variety of cancers and their treatments.
Idera Pharmaceuticals, Inc., today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon Merck KGaA's initiation of a Phase 1b clinical trial of IMO-2055 (EMD 1201081), an agonist of Toll-like Receptor 9 (TLR9), in combination with cisplatin, fluorouracil and cetuximab (Erbitux®) in first-line treatment of patients with squamous cell carcinoma of the head and neck (SCCHN).
CEL-SCI reported a net loss for the three months ended June 30, 2010 of ($0.6) million versus a loss of ($6.2) million during the same three months in fiscal year 2009. Net loss per basic share was ($0.00) for the three months ended June 30, 2010 versus a loss per basic share of ($0.05) during the same three months in fiscal year 2009. The loss during the quarter ended June 30, 2010 was reduced by a gain on derivative instruments of $2.75 million.
Scientists at Albert Einstein College of Medicine of Yeshiva University have received a five-year, $10.8 million grant to develop stem cell-based therapies that could be used to mitigate radiation-induced gastrointestinal syndrome - part of acute radiation syndrome (ARS) - for military personnel, first responders and the general public. The Einstein research, funded by the federal Centers for Medical Countermeasures Against Radiation, is part of a program coordinated by the National Institute of Allergy and Infectious Diseases.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.